전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved90 programs
AntibodyLimited DatastaleEli LillyPhase 2

Penpulimab combined with cetuximab (Penpulimab combined with cetuximab)

Head and Neck Neoplasms; Recurrent Disease · Head and Neck Neoplasms

#HeadandNeckNeoplasms#Antibody#Phase2#monoclonal-antibody#RecurrentDisease+1
Trials 2Status Recruiting
CGTLimited DatastaleNektar TherapeuticsPhase 1

Polymer-conjugated IL-15 Receptor Agonist NKTR-255 (Polymer-conjugated IL-15 Receptor Agonist NKTR-255)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
AntibodyLimited DatastaleJanssenPhase 2

Amivantamab and Recombinant Human Hyaluronidase (Amivantamab and Recombinant Human Hyaluronidase)

Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma · Locally Recurrent Skin Squamous Cell Car

#LocallyRecurrentSkinSquamousCell#Antibody#Phase2#monoclonal-antibody#MetastaticSkinSquamousCellCarcin+1
Trials 1Status Discontinued
CGTLimited DatastaleSumithira VasuPhase 1

Anti-CD19/CD20/CD22 CAR T-Cells (Anti-CD19/CD20/CD22 CAR T-Cells)

Recurrent Acute Lymphoblastic Leukemia; Recurrent B Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleOhio State University Comprehen…Phase 1

Anti-GARP Chimeric Antigen Receptor-T Cells (Anti-GARP Chimeric Antigen Receptor-T Cells)

Recurrent Malignant Glioma; Recurrent WHO Grade 3 Glioma · Recurrent Malignant Glioma

#RecurrentMalignantGlioma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

Anti-LILRA6 CAR-T cells (Anti-LILRA6 CAR-T cells)

Refractory Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 (Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143)

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMayo ClinicPhase 1

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 (Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563)

Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAstraZenecaPhase 1

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014 (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014)

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleRoswell Park Cancer InstitutePhase 1

Autologous Anti-CD83 CAR T-cells (Autologous Anti-CD83 CAR T-cells)

Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMayo ClinicPhase 1

Autologous BAFFR-targeting CAR T Cells (Autologous BAFFR-targeting CAR T Cells)

B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

B7-H3 CAR-T (B7-H3 CAR-T)

Recurrent Glioblastoma; Refractory Glioblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleKitePhase 2

other names: brexu-cel , Tecartus (Brexucabtagene autoleucel, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus))

Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleInstituto de Investigación Biom…Phase 2

CAR-T cells therapy (CAR-T cells therapy)

Refractory B-Cell Lymphoma; B-cell Lymphoma Recurrent · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CART-EGFR-IL13Ra2 T cells (CART-EGFR-IL13Ra2 T cells)

Recurrent Glioblastoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing JD Biotech Co. LTD.Phase 1

CD123-CAR-NK cells (CD123-CAR-NK cells)

Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia Recurrent · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSecond Military Medical Univers…Phase 2

CD19-specific chimeric antigen receptor (CD19-specific chimeric antigen receptor)

Recurrent B-Cell Tumor; Refractory B-Cell Tumor · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastalePromiCell Therapeutics, Inc.Phase 1

CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR)

Juvenile Myelomonocytic Leukemia; Recurrent Acute Biphenotypic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab and Bevacizumab (Camrelizumab and Bevacizumab)

Recurrent Glioblastoma · Recurrent Glioblastoma

#RecurrentGlioblastoma#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Discontinued
AntibodyLimited DatastaleMedical College of WisconsinPhase 3

Cyclophosphamide and Rituximab (Cyclophosphamide and Rituximab)

Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 1 Follicular Lymphoma

#RecurrentGrade1FollicularLymphom#Antibody#Phase3#monoclonal-antibody#RecurrentGrade2FollicularLymphom+1
Trials 1Status Discontinued

3 / 5 pages

← PreviousNext →